top of page


Backing, building and exiting: what the BioInvest Catalyst Dinner revealed about life sciences capital
On Wednesday 28 October, BioNSW members filled The Oriana for the BioInvest Catalyst Dinner, a candid evening with people who have backed, built and exited life sciences companies. The case study was Tetratherix (ASX: TTX). The Sydney medtech grew out of research at the University of Sydney and listed on the ASX in June 2025. It raised $25 million at $2.88 a share, valuing the company at $145 million. It was also a deliberate choice to raise less: CEO Will Knox cut the IPO fr
Nov 32 min read


BioInvest Catalyst Dinner: Turning Conversations into Capital
The latest instalment of BioNSW's BioInvest Catalyst Dinner series was held on 21 July 2026. The sell out dinner brought together life sciences leaders and investors at The Oriana Sydney, against the backdrop of Sydney Harbour Bridge and the Opera House, for an evening focused squarely on one goal: unlocking capital for the NSW biotech sector. As BioNSW Investment Committee Chair Christian Toouli reflected afterwards, “It was a fabulous event: an engaging format, a great venu
Jul 232 min read
bottom of page
